Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Context-dependent signalling of CXC chemokine receptor 4 (CXCR4) and atypical chemokine receptor 3 (ACKR3).

Heuninck J, Perpina Viciano C, Işbilir A, Caspar B, Capoferri D, Briddon SJ, Durroux T, Hill SJ, Lohse MJ, Milligan G, Pin JP, Hoffmann C.

Mol Pharmacol. 2019 May 15. pii: mol.118.115477. doi: 10.1124/mol.118.115477. [Epub ahead of print]

2.

Time-Resolved FRET-Based Assays to Characterize G Protein-Coupled Receptor Hetero-oligomer Pharmacology.

Heuninck J, Hounsou C, Dupuis E, Trinquet E, Mouillac B, Pin JP, Bonnet D, Durroux T.

Methods Mol Biol. 2019;1947:151-168. doi: 10.1007/978-1-4939-9121-1_8.

PMID:
30969415
3.

Chemoselective Acylation of Hydrazinopeptides to Access Fluorescent Probes for Time-Resolved FRET Assays on GPCRs.

Ramanoudjame SM, Esteoulle L, Riché S, Margathe JF, Durroux T, Karpenko IA, Bonnet D.

Methods Mol Biol. 2019;1947:137-147. doi: 10.1007/978-1-4939-9121-1_7.

PMID:
30969414
4.

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.

Frantz MC, Pellissier LP, Pflimlin E, Loison S, Gandía J, Marsol C, Durroux T, Mouillac B, Becker JAJ, Le Merrer J, Valencia C, Villa P, Bonnet D, Hibert M.

J Med Chem. 2018 Oct 11;61(19):8670-8692. doi: 10.1021/acs.jmedchem.8b00697. Epub 2018 Sep 24.

PMID:
30199637
5.

Profiling of orthosteric and allosteric group-III metabotropic glutamate receptor ligands on various G protein-coupled receptors with Tag-lite® assays.

Belhocine A, Veglianese P, Hounsou C, Dupuis E, Acher F, Durroux T, Goudet C, Pin JP.

Neuropharmacology. 2018 Sep 15;140:233-245. doi: 10.1016/j.neuropharm.2018.07.032. Epub 2018 Aug 9.

PMID:
30099051
6.

Oligomerization of a G protein-coupled receptor in neurons controlled by its structural dynamics.

Møller TC, Hottin J, Clerté C, Zwier JM, Durroux T, Rondard P, Prézeau L, Royer CA, Pin JP, Margeat E, Kniazeff J.

Sci Rep. 2018 Jul 10;8(1):10414. doi: 10.1038/s41598-018-28682-6.

7.

From the Promiscuous Asenapine to Potent Fluorescent Ligands Acting at a Series of Aminergic G-Protein-Coupled Receptors.

Hounsou C, Baehr C, Gasparik V, Alili D, Belhocine A, Rodriguez T, Dupuis E, Roux T, Mann A, Heissler D, Pin JP, Durroux T, Bonnet D, Hibert M.

J Med Chem. 2018 Jan 11;61(1):174-188. doi: 10.1021/acs.jmedchem.7b01220. Epub 2017 Dec 22.

PMID:
29219316
8.

V1b vasopressin receptor trafficking and signaling: Role of arrestins, G proteins and Src kinase.

Perkovska S, Méjean C, Ayoub MA, Li J, Hemery F, Corbani M, Laguette N, Ventura MA, Orcel H, Durroux T, Mouillac B, Mendre C.

Traffic. 2018 Jan;19(1):58-82. doi: 10.1111/tra.12535.

9.

Pharmacological evidence for a metabotropic glutamate receptor heterodimer in neuronal cells.

Moreno Delgado D, Møller TC, Ster J, Giraldo J, Maurel D, Rovira X, Scholler P, Zwier JM, Perroy J, Durroux T, Trinquet E, Prezeau L, Rondard P, Pin JP.

Elife. 2017 Jun 29;6. pii: e25233. doi: 10.7554/eLife.25233.

10.

Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement.

Smith N, Pietrancosta N, Davidson S, Dutrieux J, Chauveau L, Cutolo P, Dy M, Scott-Algara D, Manoury B, Zirafi O, McCort-Tranchepain I, Durroux T, Bachelerie F, Schwartz O, Münch J, Wack A, Nisole S, Herbeuval JP.

Nat Commun. 2017 Feb 9;8:14253. doi: 10.1038/ncomms14253.

11.

A Broad G Protein-Coupled Receptor Internalization Assay that Combines SNAP-Tag Labeling, Diffusion-Enhanced Resonance Energy Transfer, and a Highly Emissive Terbium Cryptate.

Levoye A, Zwier JM, Jaracz-Ros A, Klipfel L, Cottet M, Maurel D, Bdioui S, Balabanian K, Prézeau L, Trinquet E, Durroux T, Bachelerie F.

Front Endocrinol (Lausanne). 2015 Nov 9;6:167. doi: 10.3389/fendo.2015.00167. eCollection 2015.

12.

Design and validation of a homogeneous time-resolved fluorescence cell-based assay targeting the ligand-gated ion channel 5-HT3A.

Blanc E, Wagner P, Plaisier F, Schmitt M, Durroux T, Bourguignon JJ, Partiseti M, Dupuis E, Bihel F.

Anal Biochem. 2015 Sep 1;484:105-12. doi: 10.1016/j.ab.2015.03.035. Epub 2015 May 18.

PMID:
25998104
13.

Multicolor time-resolved Förster resonance energy transfer microscopy reveals the impact of GPCR oligomerization on internalization processes.

Faklaris O, Cottet M, Falco A, Villier B, Laget M, Zwier JM, Trinquet E, Mouillac B, Pin JP, Durroux T.

FASEB J. 2015 Jun;29(6):2235-46. doi: 10.1096/fj.14-260059. Epub 2015 Feb 17.

PMID:
25690655
14.

Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.

Karpenko IA, Margathe JF, Rodriguez T, Pflimlin E, Dupuis E, Hibert M, Durroux T, Bonnet D.

J Med Chem. 2015 Mar 12;58(5):2547-52. doi: 10.1021/jm501395b. Epub 2015 Feb 12.

PMID:
25642985
15.

Time-resolved FRET strategy to screen GPCR ligand library.

Oueslati N, Hounsou C, Belhocine A, Rodriguez T, Dupuis E, Zwier JM, Trinquet E, Pin JP, Durroux T.

Methods Mol Biol. 2015;1272:23-36. doi: 10.1007/978-1-4939-2336-6_2.

PMID:
25563174
16.

Untangling dopamine-adenosine receptor-receptor assembly in experimental parkinsonism in rats.

Fernández-Dueñas V, Taura JJ, Cottet M, Gómez-Soler M, López-Cano M, Ledent C, Watanabe M, Trinquet E, Pin JP, Luján R, Durroux T, Ciruela F.

Dis Model Mech. 2015 Jan;8(1):57-63. doi: 10.1242/dmm.018143. Epub 2014 Nov 14.

17.

Time-resolved FRET binding assay to investigate hetero-oligomer binding properties: proof of concept with dopamine D1/D3 heterodimer.

Hounsou C, Margathe JF, Oueslati N, Belhocine A, Dupuis E, Thomas C, Mann A, Ilien B, Rognan D, Trinquet E, Hibert M, Pin JP, Bonnet D, Durroux T.

ACS Chem Biol. 2015 Feb 20;10(2):466-74. doi: 10.1021/cb5007568. Epub 2014 Nov 11.

PMID:
25350273
18.

Fluorescent ligands to investigate GPCR binding properties and oligomerization.

Cottet M, Faklaris O, Falco A, Trinquet E, Pin JP, Mouillac B, Durroux T.

Biochem Soc Trans. 2013 Feb 1;41(1):148-53. doi: 10.1042/BST20120237.

PMID:
23356275
19.

Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.

Loison S, Cottet M, Orcel H, Adihou H, Rahmeh R, Lamarque L, Trinquet E, Kellenberger E, Hibert M, Durroux T, Mouillac B, Bonnet D.

J Med Chem. 2012 Oct 25;55(20):8588-602. doi: 10.1021/jm3006146. Epub 2012 Oct 5.

PMID:
22984902
20.

BRET and Time-resolved FRET strategy to study GPCR oligomerization: from cell lines toward native tissues.

Cottet M, Faklaris O, Maurel D, Scholler P, Doumazane E, Trinquet E, Pin JP, Durroux T.

Front Endocrinol (Lausanne). 2012 Jul 23;3:92. doi: 10.3389/fendo.2012.00092. eCollection 2012.

21.

Nephrogenic syndrome of inappropriate antidiuresis.

Morin D, Tenenbaum J, Ranchin B, Durroux T.

Int J Pediatr. 2012;2012:937175. doi: 10.1155/2012/937175. Epub 2012 Feb 28.

22.

Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy.

Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, Sharma KS, Durand G, Pucci B, Trinquet E, Zwier JM, Deupi X, Bron P, Banères JL, Mouillac B, Granier S.

Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6733-8. doi: 10.1073/pnas.1201093109. Epub 2012 Apr 9.

23.

Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.

Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G.

J Neuroendocrinol. 2012 Apr;24(4):609-28. doi: 10.1111/j.1365-2826.2012.02303.x. Review.

24.

Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization.

Cottet M, Albizu L, Comps-Agrar L, Trinquet E, Pin JP, Mouillac B, Durroux T.

Methods Mol Biol. 2011;746:373-87. doi: 10.1007/978-1-61779-126-0_21.

PMID:
21607869
25.

The oligomeric state sets GABA(B) receptor signalling efficacy.

Comps-Agrar L, Kniazeff J, Nørskov-Lauritsen L, Maurel D, Gassmann M, Gregor N, Prézeau L, Bettler B, Durroux T, Trinquet E, Pin JP.

EMBO J. 2011 May 6;30(12):2336-49. doi: 10.1038/emboj.2011.143.

26.

A fluorescent ligand-binding alternative using Tag-lite® technology.

Zwier JM, Roux T, Cottet M, Durroux T, Douzon S, Bdioui S, Gregor N, Bourrier E, Oueslati N, Nicolas L, Tinel N, Boisseau C, Yverneau P, Charrier-Savournin F, Fink M, Trinquet E.

J Biomol Screen. 2010 Dec;15(10):1248-59. doi: 10.1177/1087057110384611. Epub 2010 Oct 25.

PMID:
20974902
27.

Familial nephrogenic syndrome of inappropriate antidiuresis: dissociation between aquaporin-2 and vasopressin excretion.

Ranchin B, Boury-Jamot M, Blanchard G, Dubourg L, Hadj-Aïssa A, Morin D, Durroux T, Cochat P, Bricca G, Verbavatz JM, Geelen G.

J Clin Endocrinol Metab. 2010 Sep;95(9):E37-43. doi: 10.1210/jc.2009-2524. Epub 2010 Jul 14.

PMID:
20631022
28.

Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.

Albizu L, Cottet M, Kralikova M, Stoev S, Seyer R, Brabet I, Roux T, Bazin H, Bourrier E, Lamarque L, Breton C, Rives ML, Newman A, Javitch J, Trinquet E, Manning M, Pin JP, Mouillac B, Durroux T.

Nat Chem Biol. 2010 Aug;6(8):587-94. doi: 10.1038/nchembio.396. Epub 2010 Jul 11.

29.

The metabotropic glutamate receptor mGlu7 activates phospholipase C, translocates munc-13-1 protein, and potentiates glutamate release at cerebrocortical nerve terminals.

Martín R, Durroux T, Ciruela F, Torres M, Pin JP, Sánchez-Prieto J.

J Biol Chem. 2010 Jun 4;285(23):17907-17. doi: 10.1074/jbc.M109.080838. Epub 2010 Apr 7.

30.

Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.

Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M.

J Med Chem. 2010 Feb 25;53(4):1546-62. doi: 10.1021/jm901084f.

PMID:
20104850
31.

The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation.

Tenenbaum J, Ayoub MA, Perkovska S, Adra-Delenne AL, Mendre C, Ranchin B, Bricca G, Geelen G, Mouillac B, Durroux T, Morin D.

PLoS One. 2009 Dec 21;4(12):e8383. doi: 10.1371/journal.pone.0008383.

32.

Leukotriene BLT2 receptor monomers activate the G(i2) GTP-binding protein more efficiently than dimers.

Arcemisbéhère L, Sen T, Boudier L, Balestre MN, Gaibelet G, Detouillon E, Orcel H, Mendre C, Rahmeh R, Granier S, Vivès C, Fieschi F, Damian M, Durroux T, Banères JL, Mouillac B.

J Biol Chem. 2010 Feb 26;285(9):6337-47. doi: 10.1074/jbc.M109.083477. Epub 2009 Dec 21.

33.

Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes.

Cottet M, Albizu L, Perkovska S, Jean-Alphonse F, Rahmeh R, Orcel H, Méjean C, Granier S, Mendre C, Mouillac B, Durroux T.

Curr Opin Pharmacol. 2010 Feb;10(1):59-66. doi: 10.1016/j.coph.2009.10.003. Epub 2009 Nov 5. Review.

PMID:
19896898
34.

Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.

Jean-Alphonse F, Perkovska S, Frantz MC, Durroux T, Méjean C, Morin D, Loison S, Bonnet D, Hibert M, Mouillac B, Mendre C.

J Am Soc Nephrol. 2009 Oct;20(10):2190-203. doi: 10.1681/ASN.2008121289. Epub 2009 Sep 3.

35.

Building a new conceptual framework for receptor heteromers.

Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, Mackie K, Milligan G, Pfleger KD, Pin JP, Volkow ND, Waldhoer M, Woods AS, Franco R.

Nat Chem Biol. 2009 Mar;5(3):131-4. doi: 10.1038/nchembio0309-131.

36.

Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane.

Orcel H, Albizu L, Perkovska S, Durroux T, Mendre C, Ansanay H, Mouillac B, Rabié A.

Mol Pharmacol. 2009 Mar;75(3):637-47. doi: 10.1124/mol.108.049031. Epub 2008 Dec 1.

PMID:
19047484
37.
38.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.

Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8. Review.

PMID:
18655903
39.

Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization.

Maurel D, Comps-Agrar L, Brock C, Rives ML, Bourrier E, Ayoub MA, Bazin H, Tinel N, Durroux T, Prézeau L, Trinquet E, Pin JP.

Nat Methods. 2008 Jun;5(6):561-7. doi: 10.1038/nmeth.1213. Epub 2008 May 18.

40.

Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.

Albizu L, Teppaz G, Seyer R, Bazin H, Ansanay H, Manning M, Mouillac B, Durroux T.

J Med Chem. 2007 Oct 4;50(20):4976-85. Epub 2007 Sep 12.

PMID:
17850055
41.

Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors.

Rodrigo J, Pena A, Murat B, Trueba M, Durroux T, Guillon G, Rognan D.

Mol Endocrinol. 2007 Feb;21(2):512-23. Epub 2006 Nov 2.

PMID:
17082326
42.

D-myo-inositol 1-phosphate as a surrogate of D-myo-inositol 1,4,5-tris phosphate to monitor G protein-coupled receptor activation.

Trinquet E, Fink M, Bazin H, Grillet F, Maurin F, Bourrier E, Ansanay H, Leroy C, Michaud A, Durroux T, Maurel D, Malhaire F, Goudet C, Pin JP, Naval M, Hernout O, Chrétien F, Chapleur Y, Mathis G.

Anal Biochem. 2006 Nov 1;358(1):126-35. Epub 2006 Aug 30.

PMID:
16965760
43.

Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding.

Albizu L, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B, Barberis C, Durroux T.

Mol Pharmacol. 2006 Nov;70(5):1783-91. Epub 2006 Aug 22.

PMID:
16926282
44.
45.

Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.

Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C.

J Pept Sci. 2005 Oct;11(10):593-608.

PMID:
15880385
46.

Key amino acids located within the transmembrane domains 5 and 7 account for the pharmacological specificity of the human V1b vasopressin receptor.

Derick S, Pena A, Durroux T, Wagnon J, Serradeil-Le Gal C, Hibert M, Rognan D, Guillon G.

Mol Endocrinol. 2004 Nov;18(11):2777-89. Epub 2004 Jul 29.

PMID:
15284336
47.

Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis.

Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, Jockers R, Barberis C, Bouvier M.

Mol Endocrinol. 2003 Apr;17(4):677-91. Epub 2002 Dec 23.

PMID:
12554793
48.

Expression of human vasopressin and oxytocin receptors in Escherichia coli.

Mouillac B, Sen T, Durroux T, Gaibelet G, Barberis C.

Prog Brain Res. 2002;139:163-77. Review.

PMID:
12436934
49.

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T.

J Med Chem. 2002 Jun 6;45(12):2579-88.

PMID:
12036367
50.

Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor.

Breton C, Chellil H, Kabbaj-Benmansour M, Carnazzi E, Seyer R, Phalipou S, Morin D, Durroux T, Zingg H, Barberis C, Mouillac B.

J Biol Chem. 2001 Jul 20;276(29):26931-41. Epub 2001 May 3.

Supplemental Content

Loading ...
Support Center